{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:30:21Z","timestamp":1761093021930,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.urolonc.2020.03.009","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T01:01:47Z","timestamp":1586394107000},"page":"684.e17-684.e24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Gu\u00e9rin in patients with high-risk non-muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"38","author":[{"given":"Naoki","family":"Fujita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Momota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Tobisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1098-407X","authenticated-orcid":false,"given":"Tohru","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.03.009_bib0001","doi-asserted-by":"crossref","DOI":"10.1111\/iju.14082","article-title":"Predictive biomarkers for drug response in bladder cancer","author":"Yoshida","year":"2019","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2020.03.009_bib0002","doi-asserted-by":"crossref","DOI":"10.1111\/iju.14105","article-title":"Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: a web-based survey","author":"Choo","year":"2019","journal-title":"Int J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.03.009_bib0003","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/iju.13532","article-title":"Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naive stage T1 high-grade urothelial bladder cancer","volume":"25","author":"Otto","year":"2018","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.03.009_bib0004","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.03.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.03.009_bib0006","article-title":"Update on the guideline of guidelines: non-muscle invasive bladder cancer","author":"Taylor","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.03.009_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006885.pub2","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer","author":"Shang","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.urolonc.2020.03.009_bib0008","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/iju.13410","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin instillation in non-muscle-invasive bladder cancer: a review","volume":"25","author":"Saluja","year":"2018","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.03.009_bib0009","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1464-410X.2012.11754.x","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy for genitourinary cancer","volume":"112","author":"Gandhi","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.03.009_bib0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.urology.2018.07.055","article-title":"Utilization of Bacillus Calmette-Guerin for nonmuscle invasive bladder cancer in an Era of Bacillus Calmette-Guerin supply shortages","volume":"124","author":"Khanna","year":"2019","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.urolonc.2020.03.009_bib0011","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/j.clgc.2019.01.007","article-title":"Determinants of guideline-based treatment in patients with cT1 bladder cancer","volume":"17","author":"Balakrishnan","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2020.03.009_bib0012","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.03.009_bib0013","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.03.009_bib0014","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0090-4295(98)00212-X","volume":"52","author":"Witjes","year":"1998","journal-title":"Urology."},{"issue":"2","key":"10.1016\/j.urolonc.2020.03.009_bib0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2020.03.009_bib0016","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1046\/j.1464-410x.2000.00911.x","article-title":"The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer","volume":"86","author":"Yamamoto","year":"2000","journal-title":"BJU Int"},{"issue":"29","key":"10.1016\/j.urolonc.2020.03.009_bib0017","doi-asserted-by":"crossref","first-page":"45479","DOI":"10.18632\/oncotarget.9991","article-title":"Single, immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials using different drugs","volume":"7","author":"Kang","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.urolonc.2020.03.009_bib0018","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0090-4295(88)90317-2","article-title":"Comparative investigation on use of (2\u2032'R)-4\u2032-O-tetrahydropyranyl-adriamycin and adriamycin as intravesical chemotherapy for superficial bladder tumors","volume":"32","author":"Akaza","year":"1988","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.urolonc.2020.03.009_bib0019","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00345-018-2196-8","article-title":"Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation","volume":"36","author":"Tanimoto","year":"2018","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.03.009_bib0020","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.urolonc.2020.03.009_bib0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10156-010-0088-y","article-title":"Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells","volume":"17","author":"Maruyama","year":"2011","journal-title":"J Infect Chemother"},{"issue":"42","key":"10.1016\/j.urolonc.2020.03.009_bib0022","doi-asserted-by":"crossref","first-page":"e12740","DOI":"10.1097\/MD.0000000000012740","volume":"97","author":"Naya","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.urolonc.2020.03.009_bib0023","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.eururo.2007.12.033","article-title":"Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer","volume":"53","author":"Hendricksen","year":"2008","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920300934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920300934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:18:43Z","timestamp":1761041923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920300934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1078143920300934"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.03.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Gu\u00e9rin in patients with high-risk non-muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}